Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger and Private Placement
Dec 23, 2024•over 1 year ago
Contract Type
agreement
Description
Ikena Oncology, Inc. and Inmagene Biopharmaceuticals have entered into a definitive merger agreement, with a $75 million private placement to support further development of IMG-007, a monoclonal antibody targeting OX40 for the treatment of atopic dermatitis. The merger will result in approximately $175 million to support the development of IMG-007.
Related People
Suggested for you
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months